Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma

Giannakakis, T.; Ziras, N.; Kakolyris, Stylianos; Mavroudis, Dimitriοs; Androulakis, N.; Agelaki, Sofia; Parashos, M.; Sarra, E.; Dimou, Th.; Hatzidaki, Dora; Vlachonikolis, John; Georgoulias, Vassilis

doi:10.1016/s0959-8049(00)00005-8

Cited by 13 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have identified a MTD of 35 mg/m 2 for docetaxel when administered weekly and 80 mg/m 2 when administered every 3 weeks [19,20]. Exposure to increasing concentrations of docetaxel over 24 hours resulted in a plateaushaped dose response curve, suggesting that increased cell kill becomes more dependent on increased exposure duration than on concentration [21].…”

Section: Discussionmentioning

confidence: 98%

Phase Ι trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease

Tamaskar

Mekhail²,

Dreicer³

et al. 2008

Invest New Drugs

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Phase Ι trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease

Tamaskar

Mekhail²,

Dreicer³

et al. 2008

Invest New Drugs

View full text Add to dashboard Cite

show abstract

“…Chemotherapy-related nausea and vomiting(CINV)is the most common adverse reactions of Carboplatin, which is one of the middle-to-high grade emetic chemotherapeutic drugs. When the area under the curve is less than 4, the incidence of CINV is 65% [22].Diarrhea is also one of the common adverse reactions of Carboplatin-Docetaxel combination [23]. At the same time, AKI can also been seen nausea, vomiting and diarrhea as its rst symptoms [24].…”

Section: Discussionmentioning

confidence: 99%

Acute kidney failure and acute pancreatitis was caused after neoadjuvant therapy for a patient with Breast Cancer：a case report

Liang

Yao

2022

Preprint

View full text Add to dashboard Cite

Background: Acute kidney injury (AKI) is a common adverse reaction of platinum drugs in neoadjuvant chemotherapy for breast cancer patients. Approximately 30% of patients receiving cisplatin have acute kidney injury. Carboplatin have less nephrotoxic than cisplatin as the second generation platinum compound. There were AKI, nausea and vomiting, acute pancreatitis and oral ulcers occurred in a women who had intravenous carboplatin in our department.Case presentation: A 63 year-old Chinese female had neoadjuvant chemotherapy of TCbHP because of diagnosed with stage III breast invasive ductal carcinoma with axillary lymph node metastasis. Fourth day after chemotherapy, she had fatigue and nausea and then suffered from AKI, acute pancreatitis and mouth ulcers. After active treatment in the ICU and breast disease department, the patient's condition improved and was discharged.Conclusion: Although carboplatin, as a second-generation platinum drug, has less nephrotoxicity than cisplatin, it still needs special attention to avoid damage to the kidneys in clinical citation. At the same time, due to the killing effect of chemotherapeutics on the body's normal immune cells, other abnormal conditions in the body should be paid special attention to avoid more serious consequences.

show abstract

“…Regarding the docetaxel-carboplatin combination, two phase I studies have been conducted so far in order to determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTDs) of the combination [38, 39]. Two MTD levels were reached in the first study [38]: docetaxel 80 mg/m 2 and carboplatin AUC = 7 or docetaxel 100 mg/m 2 and carboplatin AUC = 6.…”

Section: Discussionmentioning

confidence: 99%

“…Two MTD levels were reached in the first study [38]: docetaxel 80 mg/m 2 and carboplatin AUC = 7 or docetaxel 100 mg/m 2 and carboplatin AUC = 6. The second study [39] established the MTD at docetaxel 60 mg/m 2 , the usually applied dose in Japan, and carboplatin AUC = 6, while they recommended carboplatin at AUC = 5.5 for further phase II testing.…”

Section: Discussionmentioning

confidence: 99%

A Phase II Study of the Docetaxel- Ifosfamide-Carboplatin Combination in Advanced Non-Small-Cell Lung Cancer

et al. 2005

View full text Add to dashboard Cite

Purpose: In the present phase II study we evaluated the docetaxel-ifosfamide-carboplatin (DICb) combination in the outpatient setting in patients with advanced non-small-cell lung cancer (NSCLC). Patients and Methods: Patients with advanced NSCLC (stages IIIB/IV), WHO performance status (PS) <2, and no prior chemotherapy were eligible. Chemotherapy drug doses were: docetaxel: 80 mg/m², ifosfamide: 3.5 g/m², and carboplatin at a target area under the curve of 5 (based on Calvert’s formula), all on day 1, followed by prophylactic G-CSF. Results: Fourty patients were entered and all are evaluable for response and toxicity: median age: 64 (48–72); PS: 1 (0–1); gender: 29 males/11 females; stages: IIIB: 13 (33%), IV: 27 (67%). Metastatic sites at diagnosis included: lymph nodes: 25; bone: 7; liver: 4; brain: 5; lung nodules: 13; adrenals: 6. Responses were as follows: 22/40 [55%; 95% confidence interval (CI), 54–81%] evaluable patients responded: 4 complete responses, 18 partial responses, 11 had stable disease, and 7 had progressive disease. The median response duration was 7 months (range 2–14 months), median time to progression 9 months (range 2–18 months) and median overall survival 11 months (range 3–46+ months). 1-year survival was 47.5%. Grade 3/4 toxicities included: neutropenia 28/40, with 12 developing grade 4 and 12% febrile neutropenia, thrombocytopenia grade 3: 3/40 and grade 4: 1/40, no grade 3 neuropathy, grade 1 CNS toxicity in 3, no renal toxicity, 8 grade 2 diarrhea and 4 grade 3 vomiting. Conclusion: In the present phase II study the DICb combination yielded important activity and good tolerability in advanced NSCLC.

show abstract

Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma

Cited by 13 publications

References 22 publications

Phase Ι trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease

Phase Ι trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease

Acute kidney failure and acute pancreatitis was caused after neoadjuvant therapy for a patient with Breast Cancer：a case report

A Phase II Study of the Docetaxel- Ifosfamide-Carboplatin Combination in Advanced Non-Small-Cell Lung Cancer

Contact Info

Product

Resources

About